Endogenous target silencing was further evaluated with antibody based detection of calpain 2 (CAPN2) silencing on VCaP prostate cancer cells transfected for 72 h on a CSMA with 96 technical replicates of four different CAPN2 and control siRNAs [Additional file 3: Supplemental Fig. S1A]. This evidence concerns the gene CAPN2 and prostate cancer.